Credit: Sprout Pharmaceuticals The approval was based on a randomized, double-blind, placebo-controlled phase 3 trial, which included 447 postmenopausal women with acquired, generalized HSDD.

Cindy Eckert first learned about hypoactive sexual desire disorder (HSDD)—the most common type of sexual dysfunction in women—while attending a conference as a cofounder of Slate Pharmaceuticals, a ...

(StatePoint) Forty-two percent of women experience sexual dysfunction -- and Hypoactive Sexual Desire Disorder (HSDD) -- characterized as frustrating low libido, is the most common form of it. It is ...

Please provide your email address to receive an email when new articles are posted on . Many midlife women experience hypoactive sexual desire disorder, which can impact both relationships and mental ...

S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual ...